FDA
-
-
-
-
-
-
-
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
-
-
-
-
-
-
-
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
-
-
-
-
-
-
-
Fractyl Health (GUTS) Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita Sustained Weight Loss After GLP-1 Discontinuation
-
-
-
-
-
-
-
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
-
-
-
-
-
-
-
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resis
-
-
-
-
-
-
-
Fractyl Health (GUTS) Receives FDA Breakthrough Device Designation for Revita
-
-
-
-
-
-
-
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

